ValiRx Annual Results 2025: Strategic Restructuring and Cost Reductions Amid Going Concern Warning

ValiRx annual results 2025: a leaner business, but funding risk still hangs over the story

ValiRx has used 2025 to do what a lot of small biotech firms talk about but do not always execute – cut costs, narrow the focus, and try to build a more commercially sensible model. On that front, there is real progress here. Administrative expenses fell by £326,577, research and development costs edged lower, and management has taken further cash-saving steps after the year end.

But there is no getting around the bigger issue. The company has flagged a material uncertainty relating to going concern, which is accountant-speak for a meaningful risk that future funding may be needed to keep the business operating as planned. For retail investors, that is the headline you cannot ignore.

Key ValiRx 2025 results: the numbers that matter most to shareholders

Metric	2025	2024
Total comprehensive loss	£2,232,160	£1,915,693
Loss per share	0.54p	1.45p
Impairment of goodwill	£598,022	Not disclosed as a charge
Administrative expenses	£1,586,837	£1,913,414
R&D costs	£229,378	£245,163
Cash at bank	£791,612	£1,555,986
Turnover	£31,372	£49,775

The first thing to note is that the reported loss got worse, rising to £2,232,160 from £1,915,693. That sounds bad, and on the face of it, it is. However, that figure includes a £598,022 impairment charge on VAL401 and VAL201.

An impairment is an accounting write-down, not cash leaving the bank. Strip that out, and ValiRx says the loss would have been £1,634,138, which is £281,555 better than 2024. So the underlying direction of travel is more encouraging than the headline loss suggests.

ValiRx going concern warning: why this is the most important line in the RNS

The auditors have highlighted a material uncertainty relating to going concern, and investors should take that seriously. In plain English, ValiRx is reliant on future fund raisings to continue activities as budgeted, and if that money does not come in, there could be significant doubt over the group’s ability to continue.

That said, this is not a qualified audit opinion. The auditors specifically said their opinion is not modified in respect of this matter. That matters because it means the accounts are still signed off on a going concern basis, but with a clear warning label attached.

There is some support for management’s case. The directors say the £791,612 year-end cash balance, combined with a post-period fundraise of £1,155,000 before expenses, R&D tax credits, and cost-saving measures, should support current activity levels for at least the next 12 months from the date the accounts were approved.

Even so, this remains a cash-hungry early-stage biotech with limited revenue. Turnover was just £31,372, and gross profit was negative at £6,250. This is still a business being funded primarily by investors, not by customers.

ValiRx cost reductions and cash burn: this is where management deserves some credit

To be fair to management, they have not stood still. Administrative expenses dropped by £326,577 thanks to board reductions and redundancies, and a further £42,000 of savings has been achieved post period. There were also voluntary salary reductions and advisory board changes to trim annual cash burn further.

The operating cash outflow improved a little to £1,510,140 from £1,584,859. That is still a substantial cash drain, but at least it is moving in the right direction. In this market, discipline matters.

The problem is that cash still fell sharply, from £1,555,986 to £791,612. So yes, ValiRx is running leaner, but it is also running with a much smaller cash cushion. That is why the fundraise and future access to capital are so important.

ValiRx pipeline update: VAL401, VAL201, Cytolytix and the 3K Screen programme

This results statement is not just about cost-cutting. It is also about reshaping the pipeline and trying to get more value from existing assets.

VAL401 out-licensing deal gives ValiRx upside without carrying all the burden

One of the better pieces of news is that Ambrose Healthcare exercised its option over VAL401. ValiRx received 576,000 ordinary shares in Ambrose, equal to about 4.9% of Ambrose’s issued equity, plus staged clinical and commercial milestone payments of up to £16 million and royalties if development succeeds.

That is a sensible structure for a small biotech. ValiRx keeps exposure to upside without having to fund the full development path itself. The catch is that milestone payments are contingent, which means they are far from guaranteed.

VAL201 reset through Blue Ribbon Bio looks pragmatic, but it is still early

The TheoremRx agreement was terminated after the counterparty elected not to proceed with an amendment. That is clearly disappointing, but ValiRx says it had contingency plans in place.

The company has now formed Blue Ribbon Bio as a wholly owned subsidiary to house VAL201 and related prostate cancer assets. Modified VAL201 2.0 peptides have been designed and received post period for testing. The interesting bit here is that ValiRx is exploring ways to fund Blue Ribbon independently, which could reduce dilution pressure on existing shareholders if it works.

Still, management has written down the valuation of VAL201 to 60% of the level used in the 2024 annual report. That tells you there is still plenty to prove.

Cytolytix and CLX001 are making scientific progress, but this is pre-clinical territory

Cytolytix, the majority-owned subsidiary developing CLX001, appears to have had a useful year. The company reports patent progress in Europe and says four formulation formats are under evaluation.

That is positive because stronger intellectual property, or IP, can make a biotech asset more valuable and more partnerable. But investors should remember this is still pre-clinical work. Scientific progress is helpful, but it is not the same as commercial validation.

The 3K Screen programme could be one of the more interesting value drivers

The 3K Screen programme, run with Dominion Biotech, looks like one of the more intriguing parts of the story. Around 250 lead hits have been identified across five cancer models, narrowed to a top 10 shortlist of assets with validated human safety profiles and repositioning potential.

This matters because drug repositioning – finding new cancer uses for existing approved drugs – can be cheaper and quicker than developing a brand-new drug from scratch. If ValiRx can generate licensing interest here, it may create value without the same level of spending normally associated with early-stage biotech discovery.

Inaphaea BioLabs strategy shift: smart repositioning or retreat from revenue hopes?

ValiRx has shifted Inaphaea BioLabs away from relying heavily on third-party service revenues and towards supporting its own internal pipeline and subsidiaries. I think that is a realistic response to a tough biotech funding market, where external customers have been slow to spend.

There is a trade-off, though. Third-party service income was already below expectations, with the Amply Discovery contract bringing in about £31,000. Moving away from external revenue reliance may be strategically cleaner, but it also reinforces the fact that this is not yet a self-funding platform.

The asset underpinning the story is the PDC biobank, with over 5,000 vials, plus a growing set of data and AI-related partnerships. The TwinEdge collaboration, which uses digital twin technology and patient-derived data for in-silico drug assessment, sounds genuinely interesting. But for now, investors are still being asked to back the potential, not the profits.

What ValiRx shareholders should watch next after the 2025 final results

• Whether the post-period £1,155,000 fundraise is enough to avoid near-term pressure for more capital.
• Progress on licensing and milestone opportunities from VAL401, Blue Ribbon Bio, and the 3K Screen programme.
• Whether the new evaluation model produces commercially useful deals rather than just scientific activity.
• Any signs that Inaphaea’s biobank and AI-linked partnerships can generate meaningful revenue or licensing traction.
• Further updates on grants, as non-dilutive funding would be especially valuable here.

ValiRx AGM date and final verdict on the 2025 results

The AGM will be held at 10:00 am on 17 July 2026 at Fieldfisher LLP, Riverbank House, 2 Swan Lane, London EC4R 3TT.

My take is fairly simple. There is genuine strategic improvement here: costs are lower, the structure is cleaner, and management is trying to be much more selective and commercial. That is the good news.

The bad news is just as clear: revenue is tiny, cash has dropped hard, and the going concern warning means funding risk remains front and centre. So this RNS reads like a company that is becoming sharper and more disciplined, but which still needs capital and execution to turn potential into something shareholders can bank.

For existing investors, this is a cautious hold-the-line update rather than a full-blown breakthrough. For new investors, the science and deal flow may be interesting, but the balance sheet risk is impossible to ignore.